XML 26 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities      
Net income (loss) $ 57,138 $ (2,985) $ 629,302
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Gain from sale of Promacta license 0 0 (812,797)
Gain from sale of Vernalis R&D 0 (17,114) 0
Change in estimated fair value of contingent liabilities (36,962) 963 (30)
Depreciation of fixed assets and amortization of intangible assets 51,071 25,691 18,361
Loss (gain) short-term investments 3,997 16,933 (1,049)
Amortization/accretion of premium (discount) on investments, net 111 1,479 (10,274)
Amortization of debt discount and issuance fees 16,692 23,077 29,988
Loss on debt extinguishment 7,303 2,466 0
Amortization of commercial license and other economic rights (125) 2,275 25,370
Share-based compensation 38,783 30,727 24,515
Deferred income taxes, net (8,618) (19,053) 74,829
Other 1,572 191 (3,498)
Changes in operating assets and liabilities, net of acquisitions:      
Accounts receivable, net (28,616) (26,061) 25,463
Inventory (427) (17,799) (2,061)
Accounts payable and accrued liabilities 2,810 (1,245) (6,664)
Income taxes receivable (3,976) 9,144 (11,219)
Other economic rights 0 0 (12,000)
Deferred revenue (17,870) 29,236 (1,147)
Other (4,085) (3,339) 3,575
Net cash provided by (used in) operating activities 78,798 54,586 (29,336)
Investing activities      
Proceeds from sale of Promacta license 0 0 812,797
Cash paid for acquisition, net of cash and restricted cash acquired 0 (404,884) (11,840)
Purchases of property and equipment (8,761) (4,458) (2,553)
Purchases of short-term investments (181,325) (422,523) (2,356,545)
Proceeds from commercial license rights 494 1,358 0
Proceeds from sale of short-term investments 154,230 394,539 535,877
Proceeds from maturity of short-term investments 67,105 644,155 1,494,851
Cash paid for equity method investment 0 (500) (1,000)
Proceeds on sale of Vernalis R&D, net 0 22,061 0
Other, net (1,220) 1,900 (4,669)
Net cash provided by investing activities 30,523 231,648 466,918
Financing activities      
Repayment of debt (155,760) (222,209) (27,323)
Payments under finance lease obligations (9,188) (9,549) 0
Proceeds from bond hedge settlement 18,938 0 12,401
Payments to convert holders for bond conversion 0 0 (12,401)
Net proceeds from stock option exercises and ESPP 33,763 3,017 2,997
Taxes paid related to net share settlement of equity awards (6,018) (1,481) (4,418)
Share repurchases 0 (77,998) (453,048)
Repurchase of warrants (18,446) 0 (380)
Payments to CVR Holders (1,050) (2,325) (3,000)
Net cash used in financing activities (137,761) (310,545) (485,172)
Net decrease in cash, cash equivalents, and restricted cash (28,440) (24,311) (47,590)
Effect of exchange rate changes on cash 0 0 83
Cash, cash equivalents and restricted cash at beginning of year 47,962 72,273 119,780
Cash, cash equivalents and restricted cash at end of year 19,522 47,962 72,273
Cash paid during the year:      
Interest paid 3,028 4,463 5,827
Taxes paid 3,722 2,130 103,817
Restricted cash in other current assets 0 343 730
Supplemental schedule of non-cash investing and financing activities      
Accrued inventory purchases 1,974 1,562 170
Unrealized (loss) gain on available-for-sale investments (221) (212) 256
Purchase of fixed assets recorded in accounts payable $ 1,567 $ 249 $ 495